Last updated: October 5, 2026
Ramipril is a mature, largely commoditized ACE inhibitor with broad generic availability and minimal remaining patent protection. Its commercial trajectory is driven by prescription volume, low-cost manufacturing, tender pricing, and continued use in hypertension and cardiovascular-risk reduction rather than by brand pricing or exclusivity. The original Altace franchise has no meaningful U.S. market protection, while generic suppliers compete primarily on price, distribution reliability, and regulatory compliance.
What is ramipril and how is it used?
Ramipril is an orally administered angiotensin-converting enzyme inhibitor used to treat hypertension, reduce cardiovascular risk in selected high-risk patients, and improve survival after certain myocardial infarctions in patients with clinical heart failure or left ventricular dysfunction. It is marketed in capsules and, in some markets, oral liquid formulations.
| Attribute |
Ramipril |
| Active ingredient |
Ramipril |
| Drug class |
ACE inhibitor |
| Original brand |
Altace |
| Original innovator |
Hoechst Marion Roussel, later associated with Aventis and Sanofi |
| U.S. approval |
1991 |
| Common strengths |
1.25 mg, 2.5 mg, 5 mg, and 10 mg |
| Primary indications |
Hypertension and cardiovascular risk reduction |
| Administration |
Oral |
| Regulatory status |
Generic and multisource product |
| Biosimilar exposure |
None; ramipril is a small-molecule drug |
| Current commercial position |
Mature generic cardiovascular medicine |
The molecule is administered as a prodrug and converted to ramiprilat, the active ACE-inhibiting metabolite. It competes with lisinopril, enalapril, perindopril, benazepril, and other renin-angiotensin system medicines.
What patents protect ramipril?
The core composition-of-matter and commercial patents for ramipril have expired. No active U.S. patent estate materially restricts generic entry for the original molecule.
The principal historic U.S. patent associated with ramipril was U.S. Patent No. 4,587,258, covering ramipril-related compounds and their use. The patent was filed in the 1980s and expired after the standard patent term applicable at the time, subject to any applicable patent-term adjustments or extensions. The commercial protection period ended years before the current market cycle.
| Patent issue |
Commercial effect today |
| Core molecule patent |
Expired |
| Original compound protection |
Expired |
| Basic hypertension method claims |
Expired or commercially ineffective |
| Generic capsule products |
Widely approved |
| Formulation protection |
No material barrier to ordinary capsules |
| Manufacturing know-how |
May remain proprietary but does not block market entry |
| Biosimilar exclusivity |
Not applicable |
The precise patent history varies by jurisdiction. Country-level patent registers, supplementary protection certificates, and pediatric extensions can produce different historical expiry dates, but they do not change the current U.S. generic status.
When did ramipril lose exclusivity?
Ramipril lost effective U.S. market exclusivity in the early 2000s. Generic approvals followed the expiration or resolution of the relevant patent barriers, and multiple manufacturers entered the market.
The key commercial milestones were:
| Period |
Event |
| 1991 |
FDA approval of Altace |
| 1990s |
Expansion of Altace use in hypertension and cardiovascular-risk reduction |
| Early 2000s |
Core U.S. patent protection ended or ceased to block generic entry |
| 2002 onward |
Generic ramipril became commercially available in the United States |
| 2000s-2010s |
Rapid erosion of branded pricing and market share |
| 2010s-present |
Mature multisource generic market |
The original brand no longer has the pricing leverage associated with an exclusivity period. Any remaining branded sales are generally niche, channel-specific, or based on residual prescriber loyalty.
What is the FDA and Orange Book status of ramipril?
The FDA recognizes ramipril as an approved small-molecule active ingredient with multiple abbreviated new drug applications. Generic products are generally approved under the Abbreviated New Drug Application pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product.
Altace was the reference brand associated with the original U.S. approval. Current generic ramipril products are supplied by several manufacturers and are listed in FDA drug databases and, where applicable, the Orange Book.
The Orange Book is most relevant to historical listed patents and reference-product information. It does not give ramipril a current exclusivity position. Any active listing for an individual product would need to be evaluated at the product level, but ordinary generic ramipril capsules do not face a meaningful active-patent barrier to entry.
Does ramipril have Paragraph IV litigation risk?
Current Paragraph IV risk is low because the principal patents protecting the molecule expired long ago. Paragraph IV certifications may have been relevant during the initial generic-entry period, but they are not a material barrier to current approval or launch.
A new manufacturer could still face litigation over:
- A newly claimed formulation
- A specific liquid dosage form
- A manufacturing process
- A polymorph or crystalline form
- A combination product
- A method of use not previously covered
Those claims would not restore protection to the basic ramipril capsule market unless they were broad, valid, and commercially necessary for the product.
How many patents cover ramipril today?
No active patent count has material relevance to the ordinary ramipril capsule market. The commercially important patents have expired, and any remaining patents are more likely to concern narrow formulations, processes, or combinations than the active ingredient itself.
Patent strength is therefore low from an originator perspective and moderate only for specialized generic-product strategies. A manufacturer with a protected oral solution, fixed-dose combination, or improved stability profile could obtain some differentiation, but the market would remain exposed to substitution with standard capsules.
What formulations are protected by ramipril patents?
The standard ramipril capsule is not protected by an effective current formulation patent barrier. Potentially differentiated dosage forms include:
- Oral solutions or suspensions
- Pediatric liquid formulations
- Modified-release products
- Fixed-dose combinations with diuretics or calcium-channel blockers
- Stability-enhanced formulations
- Unit-dose or adherence-oriented packaging
Most of these opportunities face commercial constraints. Ramipril is inexpensive, physicians have many ACE inhibitor alternatives, and payers have limited incentive to reimburse a premium for a reformulated version without a clear adherence or clinical advantage.
The combination-product segment can be more commercially relevant than the single-agent market. Even there, competition from established combinations involving lisinopril, enalapril, losartan, valsartan, and amlodipine limits pricing power.
What generic entry risks exist for ramipril?
Generic entry risk is no longer a future event. It has already occurred and has structurally changed the market.
The main risks for manufacturers are operational:
- Price compression from multiple approved suppliers.
- Contract losses in pharmacy and institutional channels.
- Manufacturing-site observations or warning letters.
- Active pharmaceutical ingredient supply disruption.
- Inventory shortages caused by low-margin production.
- Substitution by other ACE inhibitors or angiotensin receptor blockers.
The market has a low legal-entry risk but a high execution risk. A supplier can obtain approval and still fail commercially if it cannot maintain reliable supply at a competitive cost.
Which companies compete in the ramipril market?
The competitive field includes generic manufacturers with broad cardiovascular portfolios. Depending on jurisdiction and product availability, suppliers have included Mylan, Teva, Sandoz, Lupin, Dr. Reddy's Laboratories, Zydus, Aurobindo, Torrent Pharmaceuticals, Cipla, Sun Pharmaceutical Industries, and other regional manufacturers.
The relevant competitive advantages are:
| Competitive factor |
Importance |
| Lowest sustainable cost |
High |
| FDA-compliant manufacturing |
High |
| Reliable API sourcing |
High |
| Wholesaler access |
High |
| Formulary position |
High |
| Brand recognition |
Low |
| Patent exclusivity |
Minimal |
| Clinical differentiation |
Low |
| Supply continuity |
Increasingly important |
The market is fragmented by country. A supplier may have a meaningful position in India, Europe, or Latin America while having limited U.S. volume. National tender systems also create sharp price differences between jurisdictions.
How does ramipril compare with competing ACE inhibitors?
Ramipril competes in a mature class with limited product differentiation.
| Drug |
Commercial comparison with ramipril |
| Lisinopril |
Often stronger generic volume and broad formulary access |
| Enalapril |
Long-established, low-cost alternative |
| Perindopril |
Stronger position in some European markets |
| Benazepril |
Used in hypertension, including combination therapy |
| Captopril |
Older product with shorter duration and more frequent dosing |
| Losartan |
ARB alternative for patients who cannot tolerate ACE inhibitors |
| Valsartan |
Major ARB competitor with broad cardiovascular use |
Ramipril retains clinical value because of evidence supporting cardiovascular-risk reduction in selected high-risk patients, including findings from the HOPE study. That evidence supports continued prescribing, but it does not create meaningful product-level pricing power because generic alternatives are widely available (Yusuf et al., 2000).
What is the financial trajectory of ramipril?
Ramipril’s financial trajectory follows the standard lifecycle of a successful small-molecule medicine:
- Launch and protected growth: Altace generated branded revenue through physician adoption and expansion into cardiovascular prevention.
- Mature brand period: Revenue depended on clinical evidence, marketing, and insurer coverage.
- Generic shock: Entry by multiple suppliers caused rapid price erosion and volume migration.
- Commodity phase: Revenue became dependent on unit volume, manufacturing cost, and contract access.
- Long-term maintenance: Demand remains stable, but gross margins are structurally lower.
Public companies generally do not report ramipril revenue as a separate line item. It is usually grouped within generic pharmaceuticals, cardiovascular products, or regional portfolios. As a result, a precise global ramipril market value cannot be derived from issuer filings alone.
The economic profile is more attractive for a low-cost manufacturer with integrated API production than for a distributor purchasing finished product. Manufacturers can preserve margin through:
- Vertical integration
- High-volume production
- Multi-country registrations
- Portfolio bundling
- Supply contracts
- Low-cost manufacturing locations
Standalone commercial investment in ramipril is unlikely to generate strong returns unless tied to a broader cardiovascular portfolio or a differentiated dosage form.
What revenue exposure does ramipril create for manufacturers?
For generic companies, ramipril is usually a low-to-moderate revenue contributor rather than a strategic growth product. Revenue exposure is most significant where the product is included in national reimbursement programs or institutional tenders.
A manufacturer’s exposure depends on:
- Country-level prescription volume
- Number of competing suppliers
- Reimbursement reference pricing
- Tender renewal cycles
- Product concentration by manufacturing site
- API sourcing arrangements
- Availability of substitute ACE inhibitors
Because the drug is inexpensive, a supply interruption can affect patient access without producing a large revenue opportunity for competitors. Short-term shortages may support temporary price increases, but they rarely create durable profitability.
What licensing deals affect ramipril?
No major current licensing transaction materially changes the commercial outlook for standard ramipril. Historic rights transfers associated with Altace and corporate consolidation affected brand ownership, but the relevant patents and brand economics have expired.
Licensing remains relevant for:
- Local marketing rights
- Regional registrations
- Combination products
- Pediatric formulations
- Contract manufacturing
- API supply
- Technology transfer
The economic value of a ramipril license is generally limited unless it includes a broader cardiovascular portfolio, a protected formulation, or access to a regulated market.
What patent litigation and settlement agreements affected ramipril?
Historic litigation focused on generic entry and the scope or validity of patents associated with Altace. Those disputes were commercially important during the transition from branded to generic supply. They no longer create a meaningful barrier to ordinary generic ramipril sales.
Current litigation risk is more likely to involve manufacturing quality, product liability, distribution, or narrow formulation claims than the expired core molecule patents.
What is the global market outlook for ramipril?
Global demand should remain stable to modestly declining in value terms. Prescription demand is supported by:
- Aging populations
- Persistent hypertension prevalence
- Cardiovascular-risk management
- Established clinical familiarity
- Low treatment cost
- Availability through public reimbursement systems
Value growth is constrained by:
- Generic substitution
- Price regulation
- Tender competition
- Substitution by ARBs
- Fixed-dose combination competition
- Low medical differentiation among ACE inhibitors
The strongest commercial opportunities are in volume-driven emerging markets, supply-constrained regions, and markets where manufacturers can combine ramipril with other cardiovascular products. Developed markets offer predictable demand but limited pricing upside.
What generic launch scenarios are plausible?
Base case
Existing suppliers retain most volume, with periodic price reductions and limited new entry. The market remains stable in units and declines gradually in value.
Low-price entrant scenario
A new supplier enters with a cost advantage and captures institutional or wholesaler contracts. Incumbents respond through price reductions, producing further margin compression.
Supply disruption scenario
A manufacturing or API interruption removes one or more suppliers. Competitors gain temporary volume, but regulatory and production requirements limit rapid replacement.
Differentiated formulation scenario
A company launches a protected oral liquid or combination product. The product captures a niche but does not materially alter the standard capsule market.
Key Takeaways
- Ramipril is a mature, multisource generic ACE inhibitor.
- Altace’s core commercial patents have expired.
- Current Paragraph IV and patent-enforcement risk for ordinary capsules is low.
- The FDA market is driven by ANDA-approved generic products.
- There is no biosimilar issue because ramipril is a small molecule.
- Revenue has shifted from branded pricing to high-volume, low-margin generic supply.
- Manufacturing reliability, API cost, and formulary access determine commercial performance.
- Standard ramipril has limited investment appeal as a standalone growth product.
- Specialized formulations and combination products offer the main routes to differentiation.
- Demand should remain durable, while market value remains under pressure from generic competition.
FAQs about ramipril patents, market share, and commercial prospects
Is ramipril still sold under the Altace brand?
Altace has largely been displaced by generic ramipril in the United States. Any remaining branded presence is commercially limited compared with the original franchise.
Can a company obtain a new patent for ramipril?
A company may patent a novel formulation, manufacturing process, combination, or delivery system if it satisfies applicable patentability standards. A new patent would not automatically restore exclusivity to the original ramipril capsule.
Is ramipril subject to biosimilar competition?
No. Ramipril is a chemically synthesized small molecule and competes through generic-drug approval pathways, not biosimilar regulation.
Which ramipril product has the strongest commercial position?
No single product has a durable global lead. Position depends on local reimbursement, supplier reliability, wholesaler contracts, and manufacturing cost.
Is ramipril a good pharmaceutical investment opportunity?
The standard molecule offers predictable demand but limited pricing power and weak exclusivity. Investment potential is stronger in integrated manufacturing, supply-constrained markets, or differentiated formulations than in ordinary generic capsule sales.
References
-
Food and Drug Administration. (1991). Altace (ramipril) prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
U.S. Patent and Trademark Office. (1986). U.S. Patent No. 4,587,258. Washington, DC.
-
Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., & Dagenais, G. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New England Journal of Medicine, 342(3), 145-153. https://doi.org/10.1056/NEJM200001203420301
